Dennis Gable, MD
Vascular Surgery · Dallas, TXNPI 1649233768
Payments from drug & device makers
Across 436 payments — averaging $1253.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- W. L. Gore & Associates, Inc.$212K
- Medtronic$172K
- Bolton Medical Inc$141K
- Arrow International, Inc.$9K
- Teleflex LLC$8K
- Silk Road Medical, Inc.$957
- plus $4K from 28 others
What the payments were for
- Consulting fees$94,72345%
- Speaking & faculty fees$69,01333%
- Travel & lodging$32,80016%
- Food & beverage$14,4537%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| W. L. Gore & Associates, Inc. | 136 | $212,283 |
| Medtronic(2 entities) | 148 | $172,126 |
| Bolton Medical Inc | 34 | $140,941 |
| Arrow International, Inc. | 9 | $8,735 |
| Teleflex LLC | 7 | $8,005 |
| Silk Road Medical, Inc. | 13 | $957 |
| Siemens Medical Solutions USA, Inc. | 4 | $522 |
| Shape Memory Medical Inc. | 3 | $416 |
| Penumbra, Inc. | 2 | $306 |
| Heartflow, Inc. | 3 | $269 |
| Johnson & Johnson | 14 | $229 |
| EKOS Corporation | 2 | $178 |
| Terumo Medical Corporation | 2 | $167 |
| Boston Scientific | 2 | $133 |
| Cvrx, Inc. | 5 | $121 |
| Stryker | 4 | $116 |
| Imperative Care, Inc | 4 | $109 |
| Sirtex Medical Inc | 6 | $96 |
| Surmodics, Inc. | 2 | $83 |
| Abbott | 4 | $82 |
| Inari Medical, Inc. | 3 | $75 |
| E.r. Squibb & Sons, L.L.C. | 6 | $72 |
| Axogen | 3 | $69 |
| Endologix LLC | 1 | $69 |
| Philips North America LLC | 3 | $62 |
| Lemaitre Vascular, Inc. | 2 | $54 |
| Reflow Medical Inc | 3 | $53 |
| Bard Peripheral Vascular, Inc. | 2 | $44 |
| Contego Medical, Inc | 2 | $36 |
| Smith+Nephew | 2 | $34 |
| Humacyte Global, Inc. | 1 | $32 |
| Pfizer | 2 | $29 |
| Convatec Inc. | 1 | $27 |
| Davol Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GORE TAG Thoracic Branch Endoprosthesis$79,076
- Valiant Navion$51,001
- MANTA$16,434
- GORE TAG Conformable Thoracic Endoprosthesis$15,030
- Product in Development$13,188
- GORE TAG Conformable Thoracic Stent Graft$11,597
- GORE EXCLUDER Iliac Branch Endoprosthesis$11,248
- EXCLUDER Conformable AAA Endoprosthesis with Active Control$10,242
- GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis$6,468
- Endurant$6,376
- ENDURANT IIS$5,099
- Valiant Captivia$2,294
- GORE TAG Thoracic Endoprosthesis$1,585
- GORE VIABAHN VBX Balloon Expandable Endo$1,487
- GORE EXCLUDER AAA Endoprosthesis$913
- GORE Embolic Filter$855
- ENROUTE Transcarotid Neuroprotection System$763
- ENROUTE Transcarotid Stent$614
- ENHANCE Transcarotid Peripheral Access Kit$424
- IMPEDE EMBOLIZATION PLUG$416
How this compares
$546,553 in reported general payments places this provider in the 95th percentile of 347 vascular surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 17 | $20,907 |
| XareltoRivaroxaban | 12 | $15,619 |
| BrilintaTicagrelor | 11 | $9,321 |
| ClopidogrelClopidogrel Bisulfate | 121 | $1,151 |
| Enoxaparin Sodium | 12 | $739 |
| Atorvastatin Calcium | 57 | $701 |
| Losartan Potassium | 15 | $231 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $29 | $20,90717 claims |
| Johnson & JohnsonXarelto | $229 | $15,61912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 347 vascular surgery providers in Texas.
Other vascular surgery in Dallas
- Gregory PearlDallas$2.3M
- Michael SiahDallas$838K
- Stephen HohmannDallas$587K
- Carlos TimaranDallas$527K
- William ShutzeDallas$106K
- Bradley GrimsleyDallas$101K
- John KedoraDallas$101K
- John EidtDallas$100K
- Alton BurnsDallas$98K
- Javier VasquezDallas$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.